WuXi AppTec (OTCMKTS:WUXAY) is a contract research, development and manufacturing organization (CRDMO) that provides services to pharmaceutical, biotechnology and medical-device companies. Its offerings span the drug-development process, including early-stage discovery, medicinal and synthetic chemistry, biology research, analytical testing, preclinical studies, clinical research support, process development and commercial manufacturing.
The company supports a broad range of therapeutic programs, with capabilities covering small-molecule drugs, biologics, chemical and pharmaceutical products, and cell and gene therapies. Its services are designed to help customers advance potential medicines from laboratory research through clinical development and production, including regulatory and quality-related support.
Founded in 2000, WuXi AppTec is headquartered in Wuxi, China, and operates research, testing and manufacturing facilities in China, the United States, Europe and other international markets. The company was founded by Dr. Ge Li, who has been associated with its leadership since its establishment. WuXi AppTec serves customers worldwide, including pharmaceutical companies, emerging biotechnology firms and medical-device developers.
